TickerTalks
Browse all tickers →
TickerTalks›$CRBU
CRCRBU

Caribou Biosciences, Inc.

$CRBU·$164M·Biotechnology·Healthcare
$1.54-4.9%YTD-5.0%1Y-18.1%
Mentions · last 7 days
2026-08-21: 5 posts2026-08-22: 1 posts2026-08-23: 3 posts2026-08-24: 1 posts29+3%
Price updated 2h ago·X counts updated 7d ago
CRCRBU
$CRBUCaribou Biosciences, Inc.
$1.54-4.94%29 posts+3%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CRBU, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellSelling offAI verdict · as of 2026-08-21

Falling on heavy selling — points lower unless it turns around.

CRISPR clinical-stage with real pipeline data but no cash runway story — the tape is telling you the market is pricing the financing, not the science.

Caribou Biosciences is a clinical-stage CRISPR cell-therapy company (lead assets CB-010 and CB-011 in blood cancers) spun out of the Doudna lab. At $164M market cap it's a story stock where the story is a specific Phase 1 dataset colliding with a specific cash-runway problem.

  • Revenue was $2.4M in Q1, essentially collaboration income — the entire equity is a bet on clinical data, so numbers like PE and P/S are meaningless here.
  • Sell-side average price target is $7.75 against a $1.61 print, roughly 4-5x upside on the base case if the pipeline reads well — but that's the bull scenario, and every clinical biotech carries a version of it until the trial actually reads.
  • Stock sits at the 11th percentile of its 52-week range and is 12% below its 200-day trend — this is technical distribution, and it usually precedes either a financing announcement or a downside surprise on data.
  • Cash burn of ~$27M/quarter against a market cap of $164M leaves an obvious dilution overhang before the next major readout — a placement done from here means real percentage dilution.

What restarts the move is a stronger CB-011 multiple-myeloma dataset or a partnership that funds Phase 3 without a straight equity raise. What confirms the breakdown is a fresh S-3/ATM at these prices — that closes the runway concern the tape is telegraphing but at a price current shareholders won't like.

Agrees with X sentimentThe mixed X read matches the setup — bulls have legitimate CB-011 data and pipeline optionality, bears have a real financing overhang with the stock at $1.69. Both sides are right about their own point; this is where you weight the financing risk higher because the tape already is.

What to watch: The next CB-011 or CB-010 data cut, and how it gets funded — a partnership deal is a very different signal from an ATM/S-3. Nov 11 Q3 print carries the runway detail.

On the calendar: 2026-11-11 — Q3 earnings and business update

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment6 posts analyzed · as of 2026-06-22

Caribou Biosciences chatter is mixed: bulls highlight strong CB-011 CaMMouflage Phase 1 clinical data in relapsed/refractory multiple myeloma with the company running a 250-patient randomized AID trial, and Rachel Haurwitz speaking at BIO Convention about expanding CAR-T access. Counter-voices express concern about the stock dropping to $1.69 with the company needing financing to fund Phase 3. With a small sample and execution overhang, the directional read is balanced.

Read the AI verdict + X sentiment for $CRBU

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops allogeneic off-the-shelf CAR-T cell therapies for cancer using CRISPR-edited donor cells.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CRBU.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $CRBU

Neutral — binary clinical-stage catalyst set is independent of the broader industry macro driver; pipeline readout timing is the company-specific event.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-100%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-11.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-53.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
17.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-100%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
94.2%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.24$-0.32+25.9%
Q1 2026May 7, 2026$-0.26$-0.33+21.2%
Q4 2025Mar 5, 2026$-0.28$-0.33+15.2%
Q3 2025Nov 12, 2025$-0.30$-0.36+16.7%
Next earningsWed, Nov 11·consensus EPS $-0.29

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$2.4M+1.9%72.9%-1096%$-0.26$-27.1M
Q4 FY25$3.9M+89.7%100%-722%$-0.28$-20.6M
Q3 FY25$2.2M+8.6%100%-1338%$-0.30$-25.3M
Q2 FY25$2.7M-23.0%100%-1784%$-0.58$-28.7M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$25.6M$4.6M – $46.7M-$1.19-$1.47 – -$0.844
FY27$30.1M$16.4M – $70.0M-$1.42-$1.43 – -$1.413
FY28$35.1M$11.5M – $100.1M-$1.77-$2.22 – -$1.344
FY29$17.5M$9.5M – $40.6M-$2.90-$7.88 – -$1.183
FY30$127.8M$69.5M – $296.6M-$3.52-$9.58 – -$1.433

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.11%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-10.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 89.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.285-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Caribou Biosciences (CRBU) held its 2026 Annual Meeting on June 17, 2026 and filed an 8-K reporting routine director election and proposal vote results. No extraordinary business or governance changes were disclosed in the excerpt.

8-KPress release / Reg FDJun 118-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Caribou Biosciences disclosed clinical data updates via Reg FD (Item 7.01) on June 11, 2026. The company released ANTLER phase 1 data for vispa-cel (anti-CD19 allogeneic CAR-T) in relapsed/refractory B-cell non-Hodgkin lymphoma and longer follow-up data from the CaMMouflage phase 1 trial for CB-011 (anti-BCMA allogeneic CAR-T) in relapsed/refractory multiple myeloma. Both datasets were presented at oral sessions at the European Hematology Association 2026 Annual Meeting in Stockholm on June 12 and 14, 2026, respectively. These readouts are material for an early-stage allogeneic cell therapy platform company; positive data could support continued development and partnering discussions.

8-KPress release / Reg FDMar 318-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

CRBU filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-03-31. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

+ 14 other (4 proxys · 3 earnings 8-Ks · 2 10-Qs · 1 13G) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75defenseworld.net·15d agoCaribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimateszacks.com·18d agoCaribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com·18d agoAre Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?zacks.com·54d agoCaribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conferenceglobenewswire.com·64d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport